Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Generic: remibrutinib
MK-462, also known as remibrutinib, is a potent, highly selective, oral Bruton's tyrosine kinase (BTK) inhibitor developed by Merck for the treatment of autoimmune diseases. It irreversibly binds to BTK, preventing B-cell activation and downstream signaling, thus mitigating the immune response that drives these conditions. This targeted approach aims to control disease activity while minimizing broader immune suppression.
Treatment of autoimmune diseases like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Most likely new formulation: Extended-release formulation (2025, 60% confidence)
Based on positive phase 2 trial results, there is a high likelihood (70-80%) of FDA approval for remibrutinib in the treatment of SLE and RA within the next 2-3 years.
BTK Inhibitor, Immunosuppressant
Pyrazolopyrimidine